The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.

Jutta Marfurt,Ivo Müller,Albert Sie,Olive Oa,John C. Reeder,Thomas J. Smith,Hans-Peter Beck,Blaise Genton

The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.

2008

Jutta Marfurt
Ivo Müller
Albert Sie
Olive Oa
John C. Reeder
Thomas J. Smith
Hans-Peter Beck
Blaise Genton

Background In Papua New Guinea (PNG), combination therapy with amodiaquine (AQ) or chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) was introduced as first-line treatment against uncomplicated malaria in 2000.

Keywords:

Sulfadoxine/pyrimethamine
Chloroquine
Plasmodium falciparum
Amodiaquine
Combination therapy
Immunology
Sulfadoxine
Pyrimethamine
Malaria
Medicine
gene mutation
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations